Ann: Quarterly report and Appendix 4C, page-33

Even without FDA approval imho GSS will sell out - everything they can make. Based on clinical studies for other indications they are up there with the QIAGEN and Roche quality. They will sell every single test they can manufacture for the foreseeable future. This puts them on track to have a t/o of circa $130m pa. The reason this is company making is because it will give them the market cap for the marketing and manufacturing support to gain very substantial share in their other tests. The largest and one of the most significant markets is STD testing. The rates of surging STD’s across the world are very real, the consequences of some of these STDs are very serious. Testing for 12 indications in one swab is a no brainer. With all medical products the question is - does the company have enough support and capital to deploy the marketing and comms needed to supply their innovation to the market. Pre-covid this was an uncertainty. Post covid imho this is an inevitable company development.